|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.44 | 89.46 | 104.56 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
416.95
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | Audited | UnAudited | Audited | Net Sales | 4,490.50 | 4,733.90 | 4,228.80 | 4,274.60 | Total Expenditure | 3,837.60 | 4,009.70 | 3,599.70 | 3,632.90 | PBIDT (Excl OI) | 652.90 | 724.20 | 629.10 | 641.70 | Other Income | 29.30 | 11.20 | 4.10 | 4.90 | Operating Profit | 682.20 | 735.40 | 633.20 | 646.60 | Interest | 100.30 | 81.00 | 77.80 | 86.40 | Exceptional Items | -82.00 | 0 | 0 | 0 | PBDT | 499.90 | 654.40 | 555.40 | 560.20 | Depreciation | 229.70 | 214.10 | 198.70 | 176.90 | Profit Before Tax | 270.20 | 440.30 | 356.70 | 383.30 | Tax | 70.10 | 108.90 | 97.30 | 129.60 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 200.10 | 331.40 | 259.40 | 253.70 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 200.10 | 331.40 | 259.40 | 253.70 | Equity Capital | 184.30 | 184.30 | 184.30 | 184.30 | Face Value (IN RS) | 2 | 2 | 2 | 2 | Reserves | | | | | Calculated EPS | 2.17 | 3.60 | 2.81 | 2.75 | Calculated EPS (Annualised) | 8.69 | 14.39 | 11.26 | 11.01 | No of Public Share Holdings | 38,019,351.00 | 38,019,351.00 | 38,030,687.00 | 38,065,687.00 | % of Public Share Holdings | 41.26 | 41.26 | 41.27 | 41.31 | | | | | | PBIDTM% (Excl OI) | 14.54 | 15.30 | 14.88 | 15.01 | PBIDTM% | 15.19 | 15.53 | 14.97 | 15.13 | PBDTM% | 11.13 | 13.82 | 13.13 | 13.11 | PBTM% | 6.02 | 9.30 | 8.44 | 8.97 | PATM% | 4.46 | 7.00 | 6.13 | 5.94 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|